Skip to content

Theravance Biopharma TBPH Price / earnings

Price / earnings at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
4.4×
Royalty Pharma logo
Royalty PharmaRPRX
24.8×+12.5×
United Therapeutics logo
United TherapeuticsUTHR
20.2×+8.8×
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
6.6×-21.1×
Organon logo
OrganonOGN
5.5×+1.8×
Innoviva, Inc. logo
Innoviva, Inc.INVA
3.4×

Other financials

Income statement

See full
Revenue$17.7M+15.0%
Operating income-$9.5M+34.3%
Net income-$4.9M+63.7%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$288.1M+160%
Total debt$40.5M-15.9%
Total equity$290.6M+75.1%
Total assets$472.3M+37.5%

Cash flow

See full
Operating cash flow$73.3M+70.3%
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation

See full
Market cap$890.32M+67.5%
Enterprise value$642.72M+37.0%
P/S8.1×0.0×

Profitability

See full
Gross margin60.8%
Operating margin1.2%+0.6pp
Net margin104.3%+71.4pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity50.2%+36.2pp
Debt / equity0.1×-0.2×
Current ratio13.1×+8.4×

Where this comes from

Calculated from Theravance Biopharma’s reported figures.

Based on the most recent quarter.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Theravance Biopharma's price / earnings?
Theravance Biopharma (TBPH) reported price / earnings of 7.3× in Q1 2026.
What does price / earnings mean?
Market capitalization at the quarter end divided by trailing-twelve-month net income. The price the market pays for each dollar of trailing earnings.